Transduction Efficiency of Pantropic Retroviral Vectors Is Controlled by the Envelope Plasmid to Vector Plasmid Ratio
- 5 September 2008
- journal article
- Published by Wiley in Biotechnology Progress
- Vol. 21 (1) , 274-282
Abstract
Pantropic retroviral vectors pseudotyped with vesicular stomatitis virus envelope G protein (VSV‐G) are typically produced by transient transfection of the VSV‐G expression plasmid because constitutive expression of VSV‐G is cytotoxic. To produce pantropic vectors, the VSV‐G expression plasmid and the vector plasmid are cotransfected into a packaging cell line, such as 293‐gag‐pol. Typically, the ratio of VSV‐G plasmid to the vector plasmid ranges from 0.33 to 1.0. However, it is not clear that this range is optimal for vector production. In this study we have systematically examined the effect of the ratio of VSV‐G plasmid (pVSV‐G) to vector plasmid on vector production. For this, 293‐gag‐pol stable packaging cells were cotransfected with pVSV‐G and an enhanced green fluorescent protein‐ (EGFP‐) expressing retroviral vector plasmid (pLTR‐EGFP) by use of lipofectamine. Vector was collected following transfection and used to transduce three target cell lines, namely, 3T3 fibroblasts, telomerase‐immortalized human diploid fibroblasts (HDF), and the human hepatoma cell line HuH7. Transduction efficiency was evaluated for vectors produced at different pVSV‐G:pLTR‐EGFP ratios such that the total amount of plasmid transfected into 293‐gag‐pol cells was kept constant. Our results indicate that transduction efficiency is greatest when the pVSV‐G:pLTR‐EGFP ratio is substantially below 1.0. For 3T3 and HDF cells, the maximum transduction efficiency was obtained when a ratio of pVSV‐G:pLTR‐EGFP ranging from 0.053 to 0.2 was used for transfection. The relative magnitude of this effect was greater for lower transduction efficiencies in control cultures. For HuH7 cells, the beneficial effects were smaller than those observed when HDF or 3T3 cells were used. The difference in transduction efficiency for vector produced under various pVSV‐G:pLTR‐EGFP ratios was not due to differences in the proliferation of packaging cells or target cells. Further characterization showed that the amount of vector RNA relative to p30gag decreased as the ratio of pVSV‐G:pLTR‐EGFP increased. These results indicate that transduction efficiency increases with increasing levels of vector RNA as long as a minimally sufficient level of pantropic envelope protein is expressed.Keywords
This publication has 21 references indexed in Scilit:
- Susceptibility of Cell Populations to Transduction by Retroviral VectorsJournal of Virology, 2004
- Metaphase Chromosome Tethering Is Necessary for the DNA Synthesis and Maintenance of oriP Plasmids but Is Insufficient for Transcription Activation by Epstein-Barr Nuclear Antigen 1Journal of Virology, 2003
- Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1–derived lentiviral vectorsBlood, 2003
- Efficiency of Onco-Retroviral and Lentiviral Gene Transfer into Primary Mouse and Human B-Lymphocytes Is Pseudotype DependentHuman Gene Therapy, 2003
- High-Level Transduction and Gene Expression in Hematopoietic Repopulating Cells Using a Human Imunodeficiency Virus Type 1-Based Lentiviral Vector Containing an Internal Spleen Focus Forming Virus PromoterHuman Gene Therapy, 2002
- Lentiviral Vectors for Sustained Transgene Expression in Human Bone Marrow–Derived Stromal CellsMolecular Therapy, 2002
- Many Nonmammalian Cells Exhibit Postentry Blocks to Transduction by Gammaretroviruses Pseudotyped with Various Viral Envelopes, Including Vesicular Stomatitis Virus G GlycoproteinJournal of Virology, 2001
- Maintenance of the Gag/Gag-Pol Ratio Is Important for Human Immunodeficiency Virus Type 1 RNA Dimerization and Viral InfectivityJournal of Virology, 2001
- Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumorGene Therapy, 2001
- Brief Report: Analysis of 4070A Envelope Levels in Retroviral Preparations and Effect on Target Cell Transduction EfficiencyHuman Gene Therapy, 2000